Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
Journal
International journal of chronic obstructive pulmonary disease
Journal Volume
17
Pages
967
Date Issued
2022
Author(s)
Hsieh, Meng-Jer
Chen, Ning-Hung
Cheng, Shih-Lung
Tao, Chi-Wei
Wei, Yu-Feng
Wu, Yao-Kuang
Chan, Ming-Cheng
Liu, Shih-Feng
Hsu, Wu-Huei
Yang, Tsung-Ming
Lin, Ming-Shian
Liu, Ching-Lung
Tsai, Ying-Huang
Abstract
Long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) combination therapy improved lung function and health-related quality-of-life and reduced exacerbation rates and dyspnea in symptomatic chronic obstructive pulmonary disease (COPD) patients. We compared the real-world effects of three fixed-dose LABA/LAMA combinations for COPD in Taiwan.
Subjects
LABA/LAMA therapy; Taiwan; chronic obstructive pulmonary disease; cohort study; indacaterol/glycopyrronium; moderate-to-severe exacerbation; propensity score matching; tiotropium/olodaterol; umeclidinium/vilanterol
Publisher
DOVE MEDICAL PRESS LTD
Type
journal article